Keros Therapeutics
$12
27
+$0.31+2.65% Today
Statistics
Day High
12.03
Day Low
11.31
52W High
22.55
52W Low
9.12
Volume
547,482
Avg. Volume
419,477
Mkt Cap
365.59M
P/E Ratio
47.56
Dividend Yield
-
Dividend
-
Upcoming
Earnings
30AprExpected
Expected EPS
-1.033333
Actual EPS
N/A
Financials
-5,277.55%Profit Margin
Unprofitable7.1MRevenue
-374.71MNet Income
Analyst Ratings
$20.50Average Price Target
The highest estimate is 27.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy 50%
Hold 50%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow KROS. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Galmed Pharmaceuticals
GLMD
Mkt Cap7.51M
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Novartis
NVS
Mkt Cap237.61B
AMGEN
AMGN
Mkt Cap160.66B
About
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Show more...
CEO
Dr. Jasbir S. Seehra Ph.D.
Employees
163
Country
US
ISIN
US4923271013
Listings
0 Comments
Share your thoughts
FAQ
What is Keros Therapeutics stock price today?▼
The current price of KROS is $12 USD — it has increased by +2.65% in the past 24 hours. Watch Keros Therapeutics stock price performance more closely on the chart.
What is Keros Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Keros Therapeutics stocks are traded under the ticker KROS.
Is Keros Therapeutics stock price growing?▼
KROS stock has risen by +8.3% compared to the previous week, the month change is a -13.73% fall, over the last year Keros Therapeutics has showed a +19.52% increase.
What is Keros Therapeutics market cap?▼
Today Keros Therapeutics has the market capitalization of 365.59M
When is the next Keros Therapeutics earnings date?▼
Keros Therapeutics is going to release the next earnings report on April 30, 2026.
What were Keros Therapeutics earnings last quarter?▼
KROS earnings for the last quarter are -0.86 USD per share, whereas the estimation was -0.7 USD resulting in a -23.36% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Keros Therapeutics revenue for the last year?▼
Keros Therapeutics revenue for the last year amounts to 7.1M USD.
What is Keros Therapeutics net income for the last year?▼
KROS net income for the last year is -374.71M USD.
How many employees does Keros Therapeutics have?▼
As of April 02, 2026, the company has 163 employees.
In which sector is Keros Therapeutics located?▼
Keros Therapeutics operates in the Health Care sector.
When did Keros Therapeutics complete a stock split?▼
Keros Therapeutics has not had any recent stock splits.
Where is Keros Therapeutics headquartered?▼
Keros Therapeutics is headquartered in Lexington, US.